This open-label phase I/II non-randomized clinical trial studies the dosimetry, efficacy, and toxicity of PSMA-targeted therapy as a neoadjuvant therapy followed by radical treatment (radical prostatectomy and pelvic node dissection after 6 weeks) in high-risk localized or locoregional advanced PCa patients. This evidence concerns the gene FOLH1 and posterior cortical atrophy.